DDInter923 DDInter542
Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory cytokine involved in chronic inflammatory diseases. Its hyperactivity and enhanced signalling pathways can be observed in inflammatory diseases where it activates further pro-inflammatory cascades. By binding to both the soluble subunit and the membrane-bound precursor of TNF-α, infliximab disrupts the interaction of TNF-α with its receptors and may also cause lysis of cells that produce TNF-α. Infliximab was first approved by the FDA in 1998 under the market name Remicade as an intravenous injection. It is indicated for the treatment
Dicoumarol is an oral anticoagulant agent that works by interfering with the metabolism of vitamin K. In addition to its clinical use, it is also used in biochemical experiments as an inhibitor of reductases.
Infliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Warfarin
Warfarin {u} (Compound) resembles {v} (Compound) Dicoumarol
Infliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Phenytoin
Phenytoin {u} (Compound) resembles {v} (Compound) Phenprocoumon
Phenprocoumon {u} (Compound) resembles {v} (Compound) Dicoumarol
Infliximab {u} may lead to a major life threatening interaction when taken with {v} Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Warfarin
Warfarin {u} (Compound) resembles {v} (Compound) Dicoumarol
Infliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Phenytoin
Phenytoin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Warfarin
Warfarin {u} (Compound) resembles {v} (Compound) Dicoumarol
Infliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fluvastatin
Fluvastatin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Warfarin
Warfarin {u} (Compound) resembles {v} (Compound) Dicoumarol
Infliximab {u} may lead to a major life threatening interaction when taken with {v} Bortezomib
Bortezomib {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Dicoumarol
Infliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Phenytoin
Phenytoin {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Dicoumarol
Infliximab {u} may lead to a major life threatening interaction when taken with {v} Mechlorethamine
Mechlorethamine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Warfarin
Warfarin {u} (Compound) resembles {v} (Compound) Dicoumarol
Infliximab {u} may lead to a major life threatening interaction when taken with {v} Bortezomib
Bortezomib {u} (Compound) downregulates {v} (Gene) VKORC1
VKORC1 {u} (Gene) is bound by {v} (Compound) Dicoumarol
Infliximab {u} may lead to a major life threatening interaction when taken with {v} Bortezomib
Bortezomib {u} (Compound) downregulates {v} (Gene) POLR2I
POLR2I {u} (Gene) is downregulated by {v} (Compound) Dicoumarol
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin (Compound) resembles Dicoumarol (Compound)
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Phenprocoumon (Compound) and Phenprocoumon (Compound) resembles Dicoumarol (Compound)
Infliximab may lead to a major life threatening interaction when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin (Compound) resembles Dicoumarol (Compound)
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin (Compound) resembles Dicoumarol (Compound)
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin and Fluvastatin may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin (Compound) resembles Dicoumarol (Compound)
Infliximab may lead to a major life threatening interaction when taken with Bortezomib and Bortezomib (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Dicoumarol (Compound)
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Dicoumarol (Compound)
Infliximab may lead to a major life threatening interaction when taken with Mechlorethamine and Mechlorethamine may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin (Compound) resembles Dicoumarol (Compound)
Infliximab may lead to a major life threatening interaction when taken with Bortezomib and Bortezomib (Compound) downregulates VKORC1 (Gene) and VKORC1 (Gene) is bound by Dicoumarol (Compound)
Infliximab may lead to a major life threatening interaction when taken with Bortezomib and Bortezomib (Compound) downregulates POLR2I (Gene) and POLR2I (Gene) is downregulated by Dicoumarol (Compound)